Adaptive Pharmacogenomics, LLC

Pharmacogenetics of tomorrow: the 1 + 1 = 3 principle.

Pharmacogenomics. 2010 Jul;11(7):1011-7

Authors: Pander J, Wessels JA, Mathijssen RH, Gelderblom H, Guchelaar HJ

Disappointing results from replicating pharmacogenetic association studies have prompted the search for novel statistical techniques to analyze the data, while taking into account the biological complexity underlying drug response.

CYP4F2 rs2108622: a minor significant genetic factor of warfarin dose in Han Chinese patients with mechanical heart valve replacement.

Br J Clin Pharmacol. 2010 Aug;70(2):234-40

Authors: Cen HJ, Zeng WT, Leng XY, Huang M, Chen X, Li JL, Huang ZY, Bi HC, Wang XD, He YL, He F, Zhou RN, Zheng QS, Zhao LZ

WHAT IS ALREADY KNOWN ABOUT THIS SUBJECT * Genetic polymorphisms of VKORC1 and CYP2C9 are known to influence warfarin dosage.

IL28B in hepatitis C virus infection: translating pharmacogenomics into clinical practice.

J Gastroenterol. 2010 Sep;45(9):903-10

Authors: Ahlenstiel G, Booth DR, George J

Three landmark genome-wide association studies (GWAS) published in 2009 identified the interleukin (IL) 28B gene locus as pivotal to the pathogenesis of hepatitis C virus (HCV) infection.

Warfarin and vitamin K intake in the era of pharmacogenetics.

Br J Clin Pharmacol. 2010 Aug;70(2):164-70

Authors: Lurie Y, Loebstein R, Kurnik D, Almog S, Halkin H

The considerable variability in the warfarin dose-response relationship between individuals, is explained mainly by genetic variation in its major metabolic (CYP2C9) and target (VKORC1) enzymes.

LILLE, France and CAMBRIDGE, Mass., Jan. 6, 2011 /PRNewswire/ -- GENFIT (Alternext: ALGFT; ISIN: FR0004163111), a biopharmaceutical company at the forefront of drug discovery and development, focusing on the early diagnosis and preventive treatment o...

Melanocortin MC(1) receptor in human genetics and model systems.

Eur J Pharmacol. 2010 Dec 31;

Authors: Beaumont KA, Wong SS, Ainger SA, Liu YY, Patel MP, Millhauser GL, Smith JJ, Alewood PF, Leonard JH, Sturm RA

The melanocortin MC(1) receptor is a G-protein coupled receptor expressed in melanocytes of the skin and hair and is known for its key role in regulation of human pigmentation.

Monoamine transporters vulnerable and vital doorkeepers.

Prog Mol Biol Transl Sci. 2011;98:1-46

Authors: Lin Z, Canales JJ, Björgvinsson T, Thomsen M, Qu H, Liu QR, Torres GE, Caine SB

Transporters of dopamine, serotonin, and norepinephrine have been empirically used as medication targets for several mental illnesses in the last decades.

[Pharmacogenetics].

Hautarzt. 2010 Aug;61(8):650-3

Authors: Merk HF

Allergic reactions to drugs belong to the group of B-reactions, which are characterized not only by the pharmacologic profile of the drug but also by individual risk factors. Pharmacogenetic approaches facilitate identifying these risk factors.

Scientists in France have performed biomarker discovery on patients being treated for chronic hepatitis C infection. Their work demonstrates that the plasma levels of the protein IP-10 predict, prior to treatment initiation, the efficacy of treatment with pegylated-interferon and ribavirin. Based on these results, the scientists have developed a prognostic test. Commercialization is anticipated in 2011.

Scientists at Inserm and Institut Pasteur have performed biomarker discovery on patients being treated for chronic hepatitis C infection. Their work, published in the Journal of Clinical Investigation, demonstrates that the plasma levels of the protein IP-10 predict, prior to treatment initiation, the efficacy of treatment with pegylated-interferon and ribavirin. Based on these results, the scientists have developed a prognostic test. Commercialization is anticipated in 2011.